Document is current
Any future updates will be listed below
-
Authors
Domingo, Christian
Palomares, Oscar
Sandham, David A.
Erpenbeck, Veit J.
Altman, Pablo
-
Funding
Funding for this research was provided by:
Novartis Pharma AG (N/A - Novartis Pharma AG supported the medical writing support of this article)
- License Information
-
More Information
Article History
Received: 24 April 2018
Accepted: 17 September 2018
First Online: 29 September 2018
Ethics approval and consent to participate
: Not applicable
: Not applicable
: Dr. Domingo reports personal fees from Novartis, GSK, AstraZeneca, and Teva, as well as non-financial support from Teva, outside of the submitted work.Dr. Palomares reports personal fees for giving scientific lectures from Allergy Therapeutics, Amgen, AstraZenenca, Inmunotek S.L, Novartis, and Stallergenes. Dr. Palomares received grants from Inmunotek S.L under collaborative public projects and has participated in advisory boards for Novartis and Sanofi Genzyme. Everything reported is outside the submitted work.Veit J. Erpenbeck is an employee of Novartis Pharma.David Sandham is a full-time employee and shareholder of Novartis Institutes for Biomedical Research and Novartis, respectively.Pablo Altman is a full-time employee of Novartis Pharmaceuticals Corporation.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
